Inspire Medical Systems Lowers FY2026 Revenue Guidance After CMS Coding Clarification, Oppenheimer Says

MT Newswires Live02-13 00:46

Inspire Medical Systems (INSP) revised its fiscal 2026 revenue guidance lower after the coding clarification by the Centers for Medicare & Medicaid Services regarding incorrect current procedural terminology coverage for hypoglossal nerve stimulation, Oppenheimer said Thursday.

Inspire Medical revised its fiscal 2026 revenue guidance to $950 million to $1 billion from $1.003 billion to $1.013 billion previously, versus Oppenheimer's estimate of $988 million and market consensus of $1.006 billion. The company estimates diluted earnings per share between $1.23 to $1.81, the report said.

Oppenheimer said a new billing code for the company's Inspire V sleep apnea treatment could take at least three years to take effect, and it remains unclear how the billing modifier could impact reimbursements. Maintaining Inspire V inventory is also a challenge, the report said.

Oppenheimer maintained a perform rating on Inspire Medical without a price target.

Shares of the company were down by more than 11% in recent trading.

Price: 60.44, Change: -7.77, Percent Change: -11.39

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611975759?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 00:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611975759","market":"sh","top_or_hot":-1,"title":"Inspire Medical Systems Lowers FY2026 Revenue Guidance After CMS Coding Clarification, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/INSP\">Inspire Medical Systems</a> (INSP) revised its fiscal 2026 revenue guidance lower after the coding clarification by the Centers for Medicare &amp; Medicaid Services regarding incorrect current procedural terminology coverage for hypoglossal nerve stimulation, Oppenheimer said Thursday.</p><p>Inspire Medical revised its fiscal 2026 revenue guidance to $950 million to $1 billion from $1.003 billion to $1.013 billion previously, versus Oppenheimer's estimate of $988 million and market consensus of $1.006 billion. The company estimates diluted earnings per share between $1.23 to $1.81, the report said.</p><p>Oppenheimer said a new billing code for the company's Inspire V sleep apnea treatment could take at least three years to take effect, and it remains unclear how the billing modifier could impact reimbursements. Maintaining Inspire V inventory is also a challenge, the report said.</p><p>Oppenheimer maintained a perform rating on Inspire Medical without a price target.</p><p>Shares of the company were down by more than 11% in recent trading.</p><p>Price: 60.44, Change: -7.77, Percent Change: -11.39</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inspire Medical Systems Lowers FY2026 Revenue Guidance After CMS Coding Clarification, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInspire Medical Systems Lowers FY2026 Revenue Guidance After CMS Coding Clarification, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-13 00:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/INSP\">Inspire Medical Systems</a> (INSP) revised its fiscal 2026 revenue guidance lower after the coding clarification by the Centers for Medicare &amp; Medicaid Services regarding incorrect current procedural terminology coverage for hypoglossal nerve stimulation, Oppenheimer said Thursday.</p><p>Inspire Medical revised its fiscal 2026 revenue guidance to $950 million to $1 billion from $1.003 billion to $1.013 billion previously, versus Oppenheimer's estimate of $988 million and market consensus of $1.006 billion. The company estimates diluted earnings per share between $1.23 to $1.81, the report said.</p><p>Oppenheimer said a new billing code for the company's Inspire V sleep apnea treatment could take at least three years to take effect, and it remains unclear how the billing modifier could impact reimbursements. Maintaining Inspire V inventory is also a challenge, the report said.</p><p>Oppenheimer maintained a perform rating on Inspire Medical without a price target.</p><p>Shares of the company were down by more than 11% in recent trading.</p><p>Price: 60.44, Change: -7.77, Percent Change: -11.39</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSP","symbol_name":"Inspire Medical Systems","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2611975759","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611975759","pubTimestamp":1770914761,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Inspire Medical Systems  revised its fiscal 2026 revenue guidance lower after the coding clarification by the Centers for Medicare & Medicaid Services regarding incorrect current procedural terminology coverage for hypoglossal nerve stimulation, Oppenheimer said Thursday.Inspire Medical revised its fiscal 2026 revenue guidance to $950 million to $1 billion from $1.003 billion to $1.013 billion previously, versus Oppenheimer's estimate of $988 million and market consensus of $1.006 billion. The company estimates diluted earnings per share between $1.23 to $1.81, the report said.Oppenheimer said a new billing code for the company's Inspire V sleep apnea treatment could take at least three years to take effect, and it remains unclear how the billing modifier could impact reimbursements. Maintaining Inspire V inventory is also a challenge, the report said.Oppenheimer maintained a perform rating on Inspire Medical without a price target.Shares of the company were down by more than 11% in re","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"INSP":"Inspire Medical Systems","OPY":"奥本海默控股","CMS":"CMS能源"},"translate_title":"奥本海默表示，CMS编码澄清后，Inspire Medical Systems下调了2026财年收入指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPY":1.5,"CMS":1.5,"INSP":1.5},"content_text":"Inspire Medical Systems (INSP) revised its fiscal 2026 revenue guidance lower after the coding clarification by the Centers for Medicare & Medicaid Services regarding incorrect current procedural terminology coverage for hypoglossal nerve stimulation, Oppenheimer said Thursday.Inspire Medical revised its fiscal 2026 revenue guidance to $950 million to $1 billion from $1.003 billion to $1.013 billion previously, versus Oppenheimer's estimate of $988 million and market consensus of $1.006 billion. The company estimates diluted earnings per share between $1.23 to $1.81, the report said.Oppenheimer said a new billing code for the company's Inspire V sleep apnea treatment could take at least three years to take effect, and it remains unclear how the billing modifier could impact reimbursements. Maintaining Inspire V inventory is also a challenge, the report said.Oppenheimer maintained a perform rating on Inspire Medical without a price target.Shares of the company were down by more than 11% in recent trading.Price: 60.44, Change: -7.77, Percent Change: -11.39","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611975759","isCrawlerRequest":true}